Denver — In the battle against melanoma, a new test has shown that it can identify primary cutaneous melanomas that are likely to metastasize in patients who had negative sentinel lymph node biopsies (SLNB). Available since mid-2013, the product (DecisionDx-Melanoma, Castle Biosciences) uses gene expression profiling (GEP).
“SLNB is currently considered the strongest single prognostic parameter for melanoma,” according to study author Pedram Gerami, M.D., who presented the data at the 72nd Annual Meeting of the American Academy of Dermatology. He is associate professor of dermatology and director of melanoma research at the Northwestern Skin Cancer Institute, Northwestern University, Chicago.
In a recent head-to-head test, “GEP testing performed superiorly to SLNB in our data set,” he says.